Pricing Log in Create free account

Ocular Therapeutix, Inc. (OCUL) vs Zenas BioPharma, Inc. (ZBIO)

Ocular Therapeutix, Inc. and Zenas BioPharma, Inc. are both Biotechnology companies. Ocular Therapeutix, Inc. and Zenas BioPharma, Inc. are of similar size ($1.7B and $1.6B). Zenas BioPharma, Inc. has the higher net margin (0.00% vs −579.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Ocular Therapeutix, Inc. leads on 6 and Zenas BioPharma, Inc. on 6.

Valuation

Metric OCUL ZBIO Biotechnology median
P/E n/m n/m 8.50
P/S 29.69 n/m 9.71
P/B 2.97 6.30 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 19.59 n/m 9.21
Earnings yield (20.67%) (36.44%) (33.15%)
Free cash flow yield (16.51%) (14.51%) (25.50%)

Profitability

Metric OCUL ZBIO Biotechnology median
Gross margin 87.11% — 65.16%
Operating margin (603.04%) 0.00% 0.00%
Net margin (579.10%) 0.00% 0.00%
Free cash flow margin (490.07%) 0.00% 0.00%
Return on equity (72.99%) (199.04%) (56.36%)
Return on assets (53.70%) (97.39%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OCUL ZBIO Biotechnology median
Revenue growth (TTM) (8.14%) — 6.02%
EPS growth (last fiscal year) (16.39%) 29.04% 30.26%
Revenue growth, 5-year CAGR 24.45% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric OCUL ZBIO Biotechnology median
Debt to equity 0.14 1.57 0.00
Current ratio 13.11 9.93 4.72
Net debt to EBITDA 2.51 0.69 0.96

Dividend

Metric OCUL ZBIO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric OCUL ZBIO Biotechnology median
Market cap 1.62b 1.66b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack